CATALANO, MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.017
NA - Nord America 3.603
EU - Europa 2.597
SA - Sud America 461
Continente sconosciuto - Info sul continente non disponibili 120
AF - Africa 97
OC - Oceania 62
Totale 10.957
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.490
CN - Cina 1.379
SG - Singapore 1.118
RU - Federazione Russa 1.028
IT - Italia 807
KR - Corea 404
HK - Hong Kong 360
BR - Brasile 357
VN - Vietnam 265
FR - Francia 151
BD - Bangladesh 132
IE - Irlanda 120
FI - Finlandia 114
DE - Germania 97
IN - India 92
GB - Regno Unito 78
CA - Canada 70
AU - Australia 58
SE - Svezia 55
ID - Indonesia 52
JP - Giappone 46
JO - Giordania 45
AR - Argentina 36
NL - Olanda 30
EC - Ecuador 28
NG - Nigeria 25
CH - Svizzera 20
BJ - Benin 19
AE - Emirati Arabi Uniti 18
AT - Austria 18
IQ - Iraq 18
TR - Turchia 18
ES - Italia 17
PL - Polonia 16
MX - Messico 14
ZA - Sudafrica 14
PK - Pakistan 12
MA - Marocco 9
SA - Arabia Saudita 9
UA - Ucraina 9
VE - Venezuela 9
MY - Malesia 8
CL - Cile 6
CO - Colombia 6
PE - Perù 6
PY - Paraguay 6
BE - Belgio 5
EG - Egitto 5
JM - Giamaica 5
KZ - Kazakistan 5
TN - Tunisia 5
UY - Uruguay 5
UZ - Uzbekistan 5
AL - Albania 4
CI - Costa d'Avorio 4
CZ - Repubblica Ceca 4
GR - Grecia 4
PH - Filippine 4
RS - Serbia 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
DO - Repubblica Dominicana 3
DZ - Algeria 3
GE - Georgia 3
GT - Guatemala 3
HN - Honduras 3
KE - Kenya 3
NI - Nicaragua 3
PT - Portogallo 3
AZ - Azerbaigian 2
BY - Bielorussia 2
CR - Costa Rica 2
FJ - Figi 2
GP - Guadalupe 2
IL - Israele 2
LK - Sri Lanka 2
LT - Lituania 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
SC - Seychelles 2
SI - Slovenia 2
SN - Senegal 2
SV - El Salvador 2
TH - Thailandia 2
TW - Taiwan 2
AO - Angola 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
BZ - Belize 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
GH - Ghana 1
GI - Gibilterra 1
GY - Guiana 1
HR - Croazia 1
IR - Iran 1
KG - Kirghizistan 1
KW - Kuwait 1
Totale 10.828
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.055
Singapore 895
Ashburn 607
Hefei 572
Seoul 404
Hong Kong 317
San Jose 240
Council Bluffs 142
Beijing 127
Dublin 118
Los Angeles 117
Milan 115
Florence 112
Rome 81
New York 80
Ho Chi Minh City 77
The Dalles 69
Kent 68
Helsinki 66
Moscow 65
Lauterbourg 64
Hanoi 56
Melbourne 54
Dallas 52
Buffalo 51
Chandler 51
Jakarta 42
Munich 38
Tokyo 38
Paris 37
Boardman 35
London 32
Shanghai 32
São Paulo 32
Bengaluru 30
Lappeenranta 28
Mumbai 27
Abuja 25
Bologna 23
Chicago 23
Frankfurt am Main 22
Figino 21
Naples 20
Cotonou 19
Toronto 19
Bremen 17
Shenzhen 16
Arezzo 15
Bern 15
Brooklyn 15
Montreal 15
Orem 15
Altamura 14
Da Nang 14
Lawrence 14
Vienna 14
Warsaw 14
Fairfield 13
Guayaquil 13
Hangzhou 13
Seattle 13
Houston 12
Wilmington 12
Atlanta 11
Biên Hòa 11
Boston 11
Brasília 11
Rio de Janeiro 11
Turku 11
Denver 10
Haiphong 10
Salt Lake City 10
Stockholm 10
Turin 10
Guangzhou 9
Brescia 8
Charlotte 8
Princeton 8
Quito 8
Tampere 8
Washington 8
Woodbridge 8
Baghdad 7
Catania 7
Decatur 7
Fortaleza 7
Johannesburg 7
Miano 7
Pescara 7
Philadelphia 7
Poplar 7
Prato 7
Pune 7
Belo Horizonte 6
Buenos Aires 6
Bắc Ninh 6
Cape Town 6
Curitiba 6
Düsseldorf 6
Huizhou 6
Totale 6.752
Salva come PNG Salva come JPEG
Nome #
Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope? 213
Current status and future perspectives in HER2 positive advanced gastric cancer 203
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin 198
Gender and Advanced Urothelial Cancer: Outcome, Efficacy and Toxicity following Chemotherapy 187
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors 186
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 186
Perineural invasion score system and clinical outcomes in resected pancreatic cancer patients 181
Germline mutations in MSH2 and ATM gene in patients with GIST (gastrointestinal stromal tumor) and second epitelial tumors 181
DNA repair deficiency as circulating biomarker in prostate cancer 179
Inflammation in Urological Malignancies: The Silent Killer 179
Systemic Sclerosis Association with Malignancy 177
Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma 177
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? 173
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 173
Immune checkpoint inhibitor-induced neurologic toxicity: a case report and literature review 172
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI 168
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment 167
Liquid biopsy in colorectal cancer: No longer young, but not yet old 163
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors 163
Targeting z-Crystallin by aspirin restores the sensitivity to cisplatin in resistant A2780 ovarian cancer cells 160
Gastric and colonic metastasis from NSCLC A very unusual case report 153
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? 152
Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy 150
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer 150
Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies 148
Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas 147
Editorial: Microbiota and metabolites in cancer immunotherapy 146
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer 145
Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments 144
Cancer management during the COVID-19 world pandemic 144
Second line of treatment for HER2-positive gastric cancer: an evolving issue 143
An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next 143
Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge 141
Antiangiogenic drugs as chemosensitizer in genitourinary cancer 140
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma 139
Reconceiving Perineural Invasion in Cutaneous Squamous Cell Carcinoma: From Biological to Histopathological Assessment 139
Editorial: Analysis of tumor immune microenvironments and molecular mechanism to reveal the dilemma of immunotherapy for advanced non-small cell lung cancer 138
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab 136
Effects of reduced extracellular sodium on proliferation and invasive activity of renal cell carcinoma cell lines 135
Impact of natremia on metastatic non small cell lung cancer patients receiving immune checkpoint inhibitors 134
Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib 133
Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine 131
The good, the bad, and the manageable: real-world outcomes with CDK4/6 inhibitors 130
Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? 128
Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers 126
Prognostic value of alkaline phosphatase and gamma-glutamyl transferase in patients with metastatic pancreatic cancer 125
First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm 124
The evolving treatment landscape of metastatic urothelial cancer 124
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials 123
Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis 123
Management Approaches for High-Risk Cutaneous Squamous Cell Carcinoma with Perineural Invasion: An Updated Review 123
Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors 123
The gut microbiome and efficacy of cancer immunotherapy 122
Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis-what is currently known? 120
Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat? 120
Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer 119
FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer 118
Antiangiogenic drugs as chemosensitizer in renal cell cancer 118
Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually? 117
Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm 114
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study 111
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study 110
The latest developments in biomarkers predicting response to immunotherapy 106
Commentary: Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of the Meet-Uro 15 study 100
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 97
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1) 95
Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis 95
Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial Cancer 93
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study 93
Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer 92
Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma 91
Evaluation of mental disorder related to colposcopy procedure during the COVID period: A cross-sectional study 88
The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer 87
Immune combinations and complete response: a new hope for metastatic renal cell carcinoma 86
Tumor microenvironment in renal cell carcinoma: what is the current impact? 85
Immunotherapy-related biomarkers: Confirmations and uncertainties 69
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study 67
Toxicity‐related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune‐based combinations (ARON‐1 study) 56
Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift 48
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights 38
Overlapping Extremes: An Analysis of Avelumab Maintenance and Pembrolizumab in Advanced Urothelial Carcinoma 35
Adjuvant immunotherapy in high-risk renal cell carcinoma: Indications, limitations, and perspectives. A consensus statement from the GIOTTO uro-oncology group 32
Current Trends in Liquid Biopsy Tracking Resistance in Molecular Breast Cancer-Targeted Therapies 31
Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients 30
Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven 27
Unraveling the role of perineural invasion in cancer-associated pain: Insights and treatment strategies 26
From treatment escalation to ultra de‐intensification: When androgen‐deprivation therapy alone remains a rational choice in metastatic hormone‐sensitive prostate cancer 26
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) 23
Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer 23
Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification 22
Efficacy and safety of trabectedin and pegylated liposomal doxorubicin in elderly patients: a subgroup analysis of a retrospective cohort 21
Serum sodium and cancer: an underrated prognostic and predictive biomarker? 20
Ulcerative colitis and colorectal cancer: Pathogenic insights and precision strategies for prevention and treatment 20
Totale 10.957
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.655
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.655
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202260 0 0 0 0 0 8 0 22 3 2 3 22
2022/2023429 10 44 6 37 15 68 97 37 53 18 16 28
2023/2024529 13 34 50 21 31 65 26 116 18 50 48 57
2024/20253.554 129 321 130 454 927 463 127 96 244 135 185 343
2025/20265.879 606 841 930 625 497 156 586 283 311 349 317 378
2026/2027470 228 242 0 0 0 0 0 0 0 0 0 0
Totale 10.957